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ABSTRACT
Objective
To identify the genetic determinants of fracture risk 
and assess the role of 15 clinical risk factors on 
osteoporotic fracture risk.
DeSiGN
Meta-analysis of genome wide association studies 
(GWAS) and a two-sample mendelian randomisation 
approach.
SettiNG
25 cohorts from Europe, United States, east Asia, and 
Australia with genome wide genotyping and fracture 
data.
ParticiPaNtS
A discovery set of 37 857 fracture cases and 227 116 
controls; with replication in up to 147 200 fracture 
cases and 150 085 controls. Fracture cases were 
defined as individuals (>18 years old) who had 
fractures at any skeletal site confirmed by medical, 
radiological, or questionnaire reports. Instrumental 
variable analyses were performed to estimate effects 
of 15 selected clinical risk factors for fracture in a two-
sample mendelian randomisation framework, using 
the largest previously published GWAS meta-analysis 
of each risk factor.
reSultS
Of 15 fracture associated loci identified, all were also 
associated with bone mineral density and mapped to 
genes clustering in pathways known to be critical to 
bone biology (eg, SOST, WNT16, and ESR1) or novel 
pathways (FAM210A, GRB10, and ETS2). Mendelian 
randomisation analyses showed a clear effect of 
bone mineral density on fracture risk. One standard 
deviation decrease in genetically determined bone 
mineral density of the femoral neck was associated 
with a 55% increase in fracture risk (odds ratio 1.55 
(95% confidence interval 1.48 to 1.63; P=1.5×10−68). 
Hand grip strength was inversely associated with 
fracture risk, but this result was not significant after 
multiple testing correction. The remaining clinical 
risk factors (including vitamin D levels) showed no 
evidence for an effect on fracture.
cONcluSiONS
This large scale GWAS meta-analysis for fracture 
identified 15 genetic determinants of fracture, all of 
which also influenced bone mineral density. Among 
the clinical risk factors for fracture assessed, only 
bone mineral density showed a major causal effect 
on fracture. Genetic predisposition to lower levels of 
vitamin D and estimated calcium intake from dairy 
sources were not associated with fracture risk.
Introduction
The United Nations recently predicted that the ratio 
of people aged 65 years and older to those aged 15-
64 years will triple globally by 2100.1 Musculoskeletal 
conditions are the most common causes of severe 
pain and physical disability, and their prevalence 
will increase with the ageing of society.2 One of the 
largest musculoskeletal burdens is attributable to 
osteoporotic fractures, the incidence of which increases 
exponentially with age.3 Therefore, the prevention of 
fractures is an important public health goal.
The causes of multifactorial common diseases, 
such as osteoporotic fractures, include genetic and 
environmental influences, as well as their interactions 
(gene by environment, or G×E). Clinically useful risk 
factors for the prediction of osteoporotic fracture 
risk need not be necessarily causal and have been 
implemented by well validated risk score algorithms 
such as FRAX4 and the Garvan5 6 fracture risk 
calculator. Yet, the extent to which modification of 
predictive clinical risk factors reduces fracture risk 
is not generally known. A better understanding of 
causal mechanisms will enable prevention strategies, 
direct the launch of proper clinical trials, and provide 
targets for effective lifestyle and pharmacological 
interventions. Acquiring this knowledge is particularly 
timely and relevant considering the increasing 
recognition that many individuals at high fracture risk 
often do not receive fracture prevention interventions.7
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WhAT IS AlReAdy knoWn on ThIS TopIC
The genetic determinants of fracture risk are not well described, and whether 
commonly used clinical risk factors for fracture are causal is not known 
For example, the effect of vitamin D supplementation in the general population 
on fracture risk is under debate; although such supplementation is part of 
clinical guidelines, recent randomised controlled trials have failed to consistently 
show a beneficial effect
WhAT ThIS STudy AddS
This mendelian randomisation study provides evidence against a causal effect 
of several proposed clinical risk factors for fractures (eg, diabetes, glucose, 
rheumatoid arthritis, and vitamin D)
Genetic predisposition to lower vitamin D levels and estimated calcium intake 
from dairy sources were not associated with fracture risk
However, these results highlight the central causal role of low bone mineral 
density in the pathophysiology of fracture risk
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Fracture risk is a moderately heritable trait (whereby 
h2 is roughly 30%),8 9 for which no large scale, genome 
wide association studies (GWAS) have been undertaken 
so far. Large GWAS meta-analyses can also be used to 
perform mendelian randomisation analyses to explore 
the causal effects of heritable risk factors on disease 
in people, while reducing bias due to confounding 
(because genetic variation is essentially randomly 
assigned at conception) or reverse causation (because 
allele assignment always precedes disease onset).10 
Conceptually similar to a randomised controlled trial, 
the mendelian randomisation approach enables an 
assessment of the cumulative effect of a genetically 
determined exposure on fracture risk, minimising the 
biases that frequently weaken observational studies.
Understanding whether interventions aimed at 
clinical risk factors would reduce fracture risk is 
important, because clinicians often ensure that such 
risk factors are optimised in individuals at high risk 
of fracture. If the risk factors are not causal, then 
such optimisation would not decrease fracture risk. 
Therefore, to better understand genetic and clinical 
risk factors for fracture, we undertook a large scale 
GWAS for fracture risk in up to 264 973 participants 
(37 857 fracture cases) in the discovery stage and 
in conjunction with the largest available GWAS for 
clinical risk factors, determined the genetic correlation 
(shared heritability) of key clinical risk factors and 
fracture. We then performed mendelian randomisation 
studies to explore the causal effect of these risk factors 
on fracture.
Methods
Study populations
A total of 23 cohorts with genome wide genotyping 
and fracture data were recruited globally through 
the GEnetic Factors for OSteoporosis consortium 
(GEFOS; http://www.gefos.org/). These cohorts were 
predominantly of European descent and from Europe 
(n=13), North America (n=8), Australia (n=1), and east 
Asia (n=1; tables S1A and S2A), and included 20 439 
fracture cases and 78 843 controls. After meta-analysis, 
replication of promising findings was performed 
initially in the GENOMOS consortium (18 779 cases 
and 32 078 controls from 29 additional studies, 
tables S1B and S2B). Two additional large GWAS (UK 
Biobank, 14 492 cases and 130 563 controls; EPIC-
Norfolk study, 2926 cases and 17 710 controls) were 
then included in the discovery set, comprising in total 
37 857 cases and 227 116 controls (aged 18-106 years, 
including 69% women). Genetic markers reaching 
genome wide significance in this expanded meta-
analysis and previously reported bone mineral density 
markers associated with fracture11 were additionally 
replicated in 147 200 cases and 150 085 controls from 
23andMe, a personal genetic company (23andMe 
GWAS participants were customers who consented 
to participate in research with self reported fracture 
data). Figure S1 shows the overall study design. To 
enable two-sample mendelian randomisation studies, 
we compiled summary level results from the largest 
available GWAS meta-analyses performed so far on a 
large set of clinical risk factors for fracture (table 1). All 
studies were approved by their respective institutional 
ethics review committees and all participants provided 
written informed consent.
Study endpoint (fracture definition)
To maximise the statistical power to detect genetic 
loci, we used an inclusive definition of fracture, which 
was successfully used in previous efforts to test bone 
mineral density associated variants for association 
with fracture11 27 and allowed us to undertake the 
largest GWAS on fracture risk so far. Fracture cases 
were defined as those individuals (>18 years old) who 
had fractures at any skeletal site confirmed by medical, 
radiological, or questionnaire reports (table S3). 
Fractures of the fingers, toes, and skull as well as high 
trauma fractures were excluded whenever possible, 
although there have been some reports that even 
high trauma fractures are also predicted by low bone 
mineral density and are predictive of future low trauma 
fracture.28 29 Controls were defined as individuals (>18 
years old) from the same cohorts, without a history of 
fracture.
Fracture GWaS meta-analysis and replication
Genome wide genotyping was performed in each 
cohort by use of Illumina or Affymetrix genome wide 
genotyping chips (table S4A) and was imputed to ensure 
accurate ascertainment of nearly all common genetic 
variation above a minor allele frequency threshold of 
1%. After strict quality control criteria were applied 
to samples and single nucleotide polymorphisms 
(SNPs), we followed a consortium wide standardised 
analytical plan to assess the association of SNPs with 
risk of fracture. We used logistic regression adjusted 
for sex, age (simple and quadratic terms), height, and 
weight, testing additive (per allele) genetic effects. 
Before performing meta-analysis, three separate meta-
analytical centres checked the data independently. All 
individual GWAS were corrected by genomic control 
table 1 | Fracture risk factors assessed and number of 
samples in each genome wide association study
Disease or trait total sample size
Femoral neck bone mineral density11 32 961
Lumbar spine bone mineral density11 31 800
Age at menopause12 69 360
Rheumatoid arthritis13 58 284 (14 361 cases)
Inflammatory bowel disease14 34 652 (12 882 cases)
Type 1 diabetes15 26 890 (9934 cases)
Thyroid stimulating hormone16 26 523
Homocysteine17 44 147
Grip strength18 142 035
Age of puberty19 182 416
Fasting glucose20 21 58 074
Coronary heart disease22 107 432 (41 513 cases)
Type 2 diabetes23 56 862 (12 171 cases)
Vitamin D levels24 25 33 996
Dairy calcium intake26* 171 213†
*Lactase intolerance (MCM6-rs4988235) was used as a proxy for dairy 
consumption.
†Effect estimates were derived from reference 26.
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before we performed a fixed effects meta-analysis using 
METAL software. A total of 2 539 801 autosomal SNPs 
present in more than two studies were meta-analysed. 
We took forward for replication a set of promising SNPs 
for de novo genotyping in 26 studies at LGC Genomics 
(UK), using KASP genotyping as described previously27 
(table S4B) and tested them in three more studies (table 
S4C), for a total of 29 studies. Allele and genotype 
frequencies of all genotyped variants followed Hardy-
Weinberg equilibrium proportions. To obtain unbiased 
estimates of effect size, all SNPs associated at a genome 
wide significant level (that is, P<5×10−8) and previously 
known bone mineral density fracture loci11 were tested 
for replication in the 23andMe cohort (table S4C).
Genetic determinants of risk factors for fracture
We used the genetic determinants of 15 available 
clinical risk factors from the largest GWAS datasets 
available. Genome wide association analyses have been 
published for bone mineral density (femoral neck and 
lumbar spine),11 age of puberty,19 age at menopause,12 
grip strength,18 vitamin D,24 25 homocysteine,17 thyroid 
stimulating hormone level,16 fasting glucose,20 21 type 
1 diabetes,15 type 2 diabetes,23 rheumatoid arthritis,13 
inflammatory bowel disease,14 and coronary artery 
disease.22 The well established lactose intolerance 
marker (LCT(C/T- 13910) polymorphism; rs4988235)
30 was 
used as a surrogate to assess long term differences in 
dairy derived calcium intake.31 Additional risk factors 
were considered for inclusion; however, at the time of 
analyses, well powered GWAS were not available for 
some risk factors of interest including alcohol intake,32 
33 smoking34 and plasma calcium levels.35 Body mass 
index36 was not evaluated given that the fracture 
discovery analysis was adjusted for body weight and 
height.
Genetic correlation
We used LD score regression to estimate the genetic 
correlation of the selected clinical risk factors and 
fracture (table 1).37 This method estimates the degree 
of shared genetic risk factors between two diseases or 
traits, and was applied to 11 of the 15 selected risk 
factors for fracture (since genome wide association 
results were not publicly available for type 1 diabetes 
and thyroid stimulating hormone and dairy calcium 
intake). We accounted for multiple testing by using a 
conservative Bonferroni correction for 12 tests (that 
is, α=4.2×10−3). We also tested whether the above 
mentioned risk factors were genetically correlated with 
bone mineral density.
Mendelian randomisation
Next, we undertook mendelian randomisation analyses 
to estimate effects of 15 selected clinical risk factors in 
a two-sample mendelian randomisation framework. 
The mendelian randomisation approach was based on 
the following assumptions: 
•	  The genetic variants used as instrumental variables are 
associated with the clinical risk factors. 
•	  The genetic variants are not associated with any 
confounders of the exposure-outcome relation. 
•	  The genetic variants are associated with fracture only 
through the clinical risk factors—that is, a lack of pleiotropy 
(fig 1). 
We used the largest previously published GWAS meta-
analyses of the risk factors, at the time of analyses, to 
maximise statistical power (table S5A).38-41 To reduce 
potential bias due to population stratification, we 
restricted the analyses to studies with participants of 
European descent. To ensure independence between 
the SNPs used to evaluate the association of the risk 
factor and fracture risk, we grouped by LD (r2>0.05) 
those SNPs achieving genome wide significance, 
keeping only the SNP with the lowest P value per group. 
Next, we recorded the effect size and standard error 
attributed to each allele’s effect on the risk factor (table 
S5B). Finally, for age of menopause, we performed sex 
specific mendelian randomisation analysis in women 
only.
The resulting individual SNP effect estimates were 
pooled by use of the Wald type ratio estimator, which 
is formally analogous to an inverse weighted meta-
analysis.42 Again, we applied a conservative Bonferroni 
corrected threshold (that is, α=3.3×10−3, because 15 
risk factors were assessed) to account for the multiple 
risk factors tested. We also tested the assumptions 
underlying the mendelian randomisation approach (fig 
1). To test the third assumption (a lack of pleiotropic 
effects of the SNPs on the outcome, independent of 
the exposure), we used mendelian randomisation-
Egger regression.43 Moreover, as sensitivity analyses 
for robust causal inference, we additionally performed 
mendelian randomisation analyses using a weighted 
median estimator and penalised weighted median 
estimator. We also tested the effect of the same 
clinical risk factors on bone mineral density27 using 
the same methods. For the binary exposures, the 
odds ratios were converted (by multiplying log-odds 
ratios by 0.693 and then exponentiating) in order 
to represent the odds ratio per doubling of the odds 
Genetic variant
Fracture
ConfoundersClinical risk factors
Clinical risk factors assessed:
1. Bone mineral density
2. Age at menopause
3. Rheumatoid arthritis
4. Inflammatory bowel disease
5. Type 1 diabetes
6. Thyroid stimulating hormone
7. Homocysteine levels
8. Grip strength
9. Age at puberty
10. Fasting glucose levels
11. Coronary heart disease
12. Type 2 diabetes
13. Vitamin D levels
14. Milk calcium intake
Assumptions of mendelian
randomisation study:
1. Genetic variants are
     associated with clinical
     risk factors
2. Genetic variants are not
     associated with
     confounders
3. Genetic variants
     influence fracture risk
     only through clinical
     risk factors
X
Fig 1 | Mendelian randomisation study design
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of susceptibility to disease.44 Finally, we undertook 
mendelian randomisation power calculations45 for all 
such analyses.
Patient involvement
No patients were directly involved in the design, 
recruitment, or conduct of the study. Nevertheless, 
several of the participating studies comprised 
collections of patients who were made aware of their 
contribution of medical data to research through their 
informed consents signed by all study participants. 
After publication, dissemination of the results will be 
sought across different countries involving respective 
patient organisations, the general public, and other 
stakeholders; typically, across social media, scientific 
meetings and media interviews. Finally, some studies 
sent newsletters informing their participants about 
important findings and their implications.
Results
Genetic loci associated with fracture
We saw was no evidence of excessive genomic inflation 
(λ=1.02, LD score intercept=0.99) in the GWAS meta-
analysis, suggesting that the results were not biased 
because of population stratification, genotyping 
artefacts, or cryptic family relationships (fig 2). As 
shown in table 2 and figure 2, 15 genomic loci were 
associated at a genome wide significant level with 
fracture risk after meta-analysis of the discovery 
(table S6A) and replication (tables S6B, S6C, and S6D) 
stages. All loci were at, or near, loci previously shown 
to be associated with bone mineral density,11 27 46-52 a 
major determinant of fracture risk (table S6E and figure 
S2). The effect sizes of these common SNPs on fracture 
risk was modest (odds ratios ranging from 1.03 to 
1.10), which is consistent with GWAS findings for other 
complex diseases.53
Genetic correlations with clinical risk factors
SNPs influencing bone mineral density were strongly 
and inversely correlated with odds of fracture (table 3; 
genetic correlation −0.59, P=2×10−24 for femoral neck 
bone mineral density, with similar results for lumbar 
spine bone mineral density, −0.53, P=1×10−20). By 
contrast, none of the remaining clinical risk factors 
evaluated was strongly genetically correlated with risk 
of fracture with the exception of homocysteine (table 
3). Genetically increased risk of type 2 diabetes was 
positively correlated with femoral neck bone mineral 
density, while genetically increased grip strength had 
positive correlations with bone mineral density of both 
the femoral neck and lumbar spine (table S7).
Mendelian randomisation
Using mendelian randomisation analyses to assess 
the effect of the 15 risk factors on fracture, we saw 
evidence for a major effect of genetically decreased 
bone mineral density on fracture risk (fig 3 and table 4; 
odds ratio per standard deviation decrease in femoral 
neck bone mineral density=1.55, 95% confidence 
interval 1.48 to 1.63, P=1.5×10−68). We also observed a 
large effect of grip strength on fracture risk (2.14, 1.13 
to 4.04, P=0.01), but these results had wide confidence 
intervals and were not significant after multiple testing 
correction. 
Vitamin D levels assessed by use of 25-hydroxy-
vitamin D variants were not found to be linearly 
associated with increased fracture risk (odds ratio per 
standard deviation decrease=0.84, 95% confidence 
interval 0.70 to 1.02, P=0.07). Most of these 
mendelian randomisation effects did not seem to be 
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Fig 2 | Manhattan plot of –log10 association P values for discovery meta-analysis, and quantile-quantile plot (QQ plot) 
of the distribution of observed −log10 association P values against the expected null distribution for discovery meta-
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loci that are within 500kb of leading SNPs in previous genome wide association studies with different bone traits. 
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strongly influenced by directional pleiotropy, because 
the intercepts of the mendelian randomisation-Egger 
test were tightly centred around the null, except for 
rheumatoid arthritis, type 2 diabetes, grip strength, 
glucose, and homocysteine levels (table 4). The 
estimates from the inverse variance weighted fixed 
meta-analysis were very similar to the estimates from 
the weighted median and penalised weighted median 
method (table S8). However, despite some indication 
of causality of fasting glucose levels on fracture risk 
(table S8) in the median weighted analyses, it did not 
surpass the multiple testing threshold. 
Consistent with the results of the genetic correlation 
analyses, we found that none of the other evaluated 
clinical risk factors had evidence of a causal effect 
on risk of fracture, despite adequate statistical power 
(mean=98% (range 56-100%), table 4).45 When 
evaluating the effect of genetically increased risk 
factors on bone mineral density (table S9), only age 
of puberty had an effect on bone mineral density after 
accounting for multiple testing; fasting glucose, type 2 
diabetes, and age at menopause had marginal effects, 
consistent with a recent mendelian randomisation 
study of type 2 diabetes and glycaemic traits on bone 
mineral density.54
We next undertook careful evaluation of the three 
mendelian randomisation assumptions. The first 
assumption was verified by the selection of only 
common variants (minor allele frequency >5%) 
strongly associated with the clinical risk factor 
(P<5×10−8). After performing a thorough literature 
search, we can exclude reported associations between 
the genetic variants and potential confounding factors 
(second assumption). Finally, by using mendelian 
randomisation-Egger regression, we found no evidence 
of the presence of pleiotropy between the instruments 
and the outcomes (table 4).
discussion
Principal findings and interpretation
In this large GWAS for fracture, we identified genetic 
determinants (at 15 loci) of fracture and tested the role 
of 15 selected clinical risk factors on fracture risk and t
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table 3 | estimated genetic correlation between fracture 
and other clinical risk factors
Disease or trait
Genetic correlation 
(95%ci) P
Femoral neck bone 
mineral density −0.59 (−0.70 to −0.48) 2×10
−24
Lumbar spine bone 
mineral density −0.53 (−0.64 to −0.42) 1×10
−20
Age at menopause −0.12 (−0.23 to −0.003) 0.04
Rheumatoid arthritis 0.02 (−0.10 to 0.14) 0.74
Inflammatory bowel 
disease −0.01 (−0.13 to 0.11) 0.90
Homocysteine levels 0.22 (0.07 to 0.37) 0.004
Grip strength −0.10 (−0.21 to 0.01) 0.07
Age of puberty 0.03 (−0.05 to 0.11) 0.43
Fasting glucose −0.05 (−0.19 to 0.09) 0.46
Coronary heart disease −0.05 (−0.09 to 0.19) 0.48
Type 2 diabetes −0.07 (−0.22 to 0.08) 0.35
Vitamin D levels 0.23 (−0.52 to 0.98) 0.56
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bone mineral density. Using mendelian randomisation 
analyses, we demonstrated that genetically decreased 
bone mineral density (and, to a lesser extent, hand 
grip strength) was the only clinical risk factor among 
those tested, with evidence for an effect on fracture 
risk. By contrast, despite high statistical power, none 
of the other tested and well accepted risk factors (eg, 
rheumatoid arthritis and other causes of secondary 
osteoporosis) or any of the other clinically relevant risk 
factors (vitamin D levels, dairy food derived calcium 
intake, fasting glucose, type 2 diabetes, and coronary 
heart disease) had evidence of a major causal effect 
on fracture risk. Furthermore, all identified genetic 
determinants of fracture also influenced bone mineral 
density.
In our previous work,11 we tested 96 bone mineral 
density markers for association with fracture. In the 
meta-analysis, 14 bone mineral density loci were 
associated with fracture risk (P<5×10−4), of which 
six surpassed genome wide significance (P<5×10−8). 
In our current project, we began with GWAS meta-
analysis for fracture risk. We confirmed the 2p16.2 
(SPTBN1), 7q21.3 (SHFM1), 10q21.1 (MBL2/DKK1), 
11q13.2 (LRP5), and 18p11.21 (FAM210A) loci, and 
observed an increased signal at SOST, CPED1/WNT16, 
FUPB3, DCDC5, RPS6KA5, STARD3NL, and CTNNB1. 
Lastly, we added the 6q22.33 (RSPO3), 6q25.1 (ESR1), 
7p12.1 (GRB10/COBL), and 21q22.2 (ETS2) loci to 
the list of novel fracture loci. Among the genome 
wide significant loci associated with fracture, several 
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Fig 3 | Forest plot showing effect of 15 genetically determined risk factors on fracture risk. Power=statistical power to 
detect an odds ratio of 1.15 at α≤3.3×10−3; Na=not applicable; bMD=bone mineral density 
table 4 | estimated effects of 15 genetically determined risk factors on fracture risk
trait or disease No of markers
inverse variance weighted meta-analysis
Power (%)‡
Mendelian randomisation-egger regression§
Odds ratio (95% ci)* P intercept (95% ci) P
Decreased femoral neck BMD¶ 43 1.55 (1.48 to 1.63) 1.5×10−68 100 −0.0010 (−0.011 to 0.008) 0.83
Decreased lumbar spine BMD¶ 40 1.43 (1.37 to 1.50) 2.3×10−55 100 0.0050 (−0.006 to 0.014) 0.93
Earlier menopause 54 1.10 (1.00 to 1.21) 0.05 100 0.0007 (−0.006 to 0.007) 0.83
Rheumatoid arthritis† 30 1.01 (1.00 to 1.02) 0.14 100 0.0099 (0.003 to 0.017) 0.005
Type 1 diabetes† 19 1.00 (1.00 to 1.01) 0.57 100 0.0028 (−0.004 to 0.010) 0.39
Inflammatory bowel disease† 151 1.00 (1.00 to 1.01) 0.92 100 0.0003 (−0.003 to 0.004) 0.86
Decreased thyroid stimulating hormone 20 0.99 (0.94 to 1.04) 0.78 100 0.0050 (−0.019 to 0.009) 0.47
Increased homocysteine levels 13 0.98 (0.92 to 1.05) 0.60 100 0.0134 (0.001 to 0.026) 0.03
Decreased grip strength 15 2.14 (1.13 to 4.04) 0.01 56 0.1070 (0.011 to 0.203) 0.03
Late puberty 106 1.06 (1.00 to 1.13) 0.04 92 0.0036 (−0.002 to 0.009) 0.21
Increased fasting glucose levels 35 1.04 (0.97 to 1.12) 0.24 100 −0.0083 (−0.014 to −0.002) 0.01
Coronary heart disease† 38 1.00 (0.99 to 1.02) 0.76 100 0.0028 (−0.007 to 0.013) 0.57
Type 2 diabetes† 38 0.99 (0.99 to 1.01) 0.37 100 −0.0089 (−0.016 to −0.002) 0.02
Decreased vitamin D levels 4 0.84 (0.70 to 1.02) 0.07 87 −0.0143 (−0.103 to 0.074) 0.56
Decreased dairy calcium intake 1 1.01 (0.80 to 1.23) 0.94 NA NA NA
NA=not applicable; BMD=bone mineral density.
*Odds ratio is for the risk of fracture per standard deviation change in the risk factor for traits (1 standard deviation change=0.13 g femoral neck BMD, 0.18 g lumbar spine BMD, 3.9 years earlier 
menopause, 0.76 mIU/L thyroid stimulating hormone, 11.3 kg grip strength, 1.42 years late puberty, 0.62 mmol/L fasting glucose, 25.2 nmol/L vitamin D), or †risk of fracture per doubling of odds 
of disease susceptibility; dairy calcium intake units are servings/day. Estimates obtained using a fixed effects model.
‡Statistical power to detect an odds ratio of 1.15 at α≤3.3×10−3.
§Egger regression analyses can be performed if the number of genetic variants is more than two; Egger effect estimates are presented in table S7.
¶Findings that remain associated (that is, α<3.3×10−3) after correction for multiple testing.
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contain well established causal proteins for fracture 
risk that are targets for clinically useful osteoporotic 
fracture treatments, such as ESR1, which encodes 
the oestrogen receptor, and SOST, which encodes 
sclerostin.55 These discoveries highlight known and 
novel factors in pathways critical to bone biology (that 
is, Wnt, for mesenchymal stem cell differentiation) as 
well as potential new factors and biological pathways 
that might constitute future drug targets.56
All the discovered fracture loci are also associated 
with bone mineral density, implying that skeletal 
fragility characterised by reduced bone mineral density 
is central to the pathophysiology of osteoporotic 
fracture. This contention is in line with the significant 
genetic correlation we identified between bone mineral 
density and fracture. Our mendelian randomisation 
analyses also indicate that the suggestive effect of 
late puberty and earlier age at menopause on fracture 
risk is, at least partly, mediated through reduced bone 
mineral density. By contrast, hand grip strength was 
not found to be a determinant of bone mineral density, 
and vice versa. Still, grip strength could be a proxy 
for overall muscle strength and risk of falling, and 
could be involved in a pathway leading to fracture 
independently of bone mineral density.56 However, the 
hand grip estimates holds wide confidence intervals 
in our analyses expressed in standard deviations to 
allow comparison to other risk factors. We believe that 
these large standard deviations can be attributed to 
multiple factors, including effort and encouragement 
of the participants, posture, position, and intrinsic 
measurement variability between individuals. A recent 
effort using UK Biobank data also showed through 
mendelian randomisation that higher grip strength 
is associated with decreased fracture risk.18 As such, 
inclusion of grip strength (or a different assessment 
of muscle function such as leg strength) could 
improve the predictive performance of risk prediction 
calculators that already contain bone mineral density, 
just as has been reported for a history of falls.56
Older individuals at high risk of fractures often have 
low levels of vitamin D (owing to low dietary intake 
and sun exposure). Therefore, fracture prevention 
guidelines have suggested the use of vitamin D 
supplementation in the general population.57 58 
These recommendations have contributed to the 
marked increase in vitamin D use in older populations 
worldwide, where in the United States alone the 
proportion of individuals aged 70 years and older who 
use at least 1000 IU of vitamin D daily increased about 
100-fold from 2000 to 2014.59 Despite these guideline 
recommendations, it is unclear whether modestly low 
levels of vitamin D, rather than profoundly low values, 
are causally associated with a higher risk of fracture. 
Our mendelian randomisation work examined a linear 
relation between vitamin D levels and fracture risk. We 
did not test for the possibility of a threshold dependent 
relation—that is, effects that could be present only at 
very low levels of vitamin D. Nevertheless, our analyses 
showed that vitamin D levels had no protective linear 
effect on fracture in community dwelling individuals, 
despite adequate statistical power. We also show, in 
line with other previous reports,60-62 no evidence for 
a causal effect of vitamin D levels on bone mineral 
density. Although a threshold effect is likely to be 
present, where profoundly lowered vitamin D levels do 
increase risk of fracture, our mendelian randomisation 
results strongly suggest that increasing levels of 
vitamin D in the (non-deficient) general population is 
unlikely to decrease risk of fracture.
Likewise, calcium supplementation has been called 
into question recently. A mendelian randomisation 
study found that higher levels of serum calcium are 
a risk factor for coronary heart disease,63 supporting 
the current recommendation of not exceeding total 
calcium intake of 1200 mg/day in older individuals.64 
Further, our study assessed the lactose persistence 
variant as a surrogate of long term intake of dairy 
calcium (used previously as an instrument for dairy 
consumption in association with blood pressure26 and 
other traits), and found no evidence for a protective 
effect of sustained intake of dairy derived calcium on 
fracture risk.
comparison with other studies
Previous observational studies and clinical trials 
have reported the beneficial effect of vitamin D65 66 or 
calcium67 supplementation on fracture risk reduction, 
findings which are not supported by our results. 
These discrepant findings can be due to inadequate 
methods or high heterogeneity induced, for example, 
by combining community dwelling participants and 
inpatients in the same analysis. Consistent with our 
findings, a recent meta-analysis of 33 randomised 
trials68 (n=51 145) found that supplementation with 
calcium, vitamin D, or both did not decrease the 
incidence of fractures in community dwelling older 
adults. Findings such as these should be interpreted 
with caution, because they do not necessarily apply 
to patients undergoing osteoporosis treatment, 
considering that trials evaluating osteoporosis 
treatment are carried out concomitant with vitamin D 
and calcium supplementation. 
Studies seeking to show whether these supplements 
do increase the efficacy of osteoporotic treatment 
or decrease adverse events (that is, hypocalcaemia) 
are lacking. In either case, screening for vitamin 
D deficiency and seeking its correction should be 
warranted before the initiation of anti-resorptive 
treatment. Moreover, in a recent mendelian 
randomisation study investigating the role of 
25-hydroxy-vitamin D in maintaining bone mineral 
density,62 increased levels of 25-hydroxy-vitamin D 
had no effect on bone mineral density measured by 
dual energy x-ray absorptiometry (n=32 965; 0.02 g/
cm2 change in femoral neck bone mineral density per 
standard deviation increase in 25-hydroxy-vitamin 
D). However, increased 25-hydroxy-vitamin D was 
associated with a slight reduction in heel bone mineral 
density estimated by ultrasonography (n=142 487; 
−0.03 g/cm2 change in estimated bone mineral density 
per standard deviation increase in 25-hydroxy-vitamin 
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D). These results are consistent with our mendelian 
randomisation findings of no causal effect of vitamin 
D levels on fracture.
implications for clinicians
Our mendelian randomisation findings are relevant 
to clinical care. Although clinical risk factors, when 
used jointly in well validated prediction algorithms, 
predict fracture risk, our findings are a reminder 
that clinically relevant changes in most of these risk 
factors are unlikely to result in large differences in 
fracture risk. These findings also suggest clinical 
outcomes such as fracture risk can be subject to bias 
owing to uncontrolled confounding in observational 
epidemiological studies. A strength of our study 
design is that mendelian randomisation limits this 
potential confounding, because alleles are essentially 
assigned randomly at conception, and are therefore 
not generally affected by confounders. Furthermore, 
because allele assignment must precede fracture, 
mendelian randomisation is not prone to bias due to 
reverse causation. These findings provide guidance for 
the design of future clinical trials on interventions that 
are more likely to be successful in reducing fracture 
risk.
Epidemiological studies have shown that older 
people with a fracture will have abnormal bone 
mineral density in the osteoporotic range (that is, T 
score lower than −2.5 standard deviations), but most 
will have a fracture will be osteopenic (T score between 
−1 and −2.5 standard deviations). In fact, about 
87% of women and 82% of men with a non-vertebral 
fracture have a T score lower than −1.0.69 Our findings 
suggest that low bone mineral density (not only after 
reaching the osteoporotic range) constitutes a risk 
factor that captures a substantial and causal part of the 
influences that increase risk for all types of fracture. 
Therefore, interventions targeting an increase in bone 
mineral density (presuming this is associated with 
improvements in bone structure or quality) are likely 
to have pivotal roles in reducing fracture risk.
The interpretation of our findings merits 
careful consideration for some of the risk factors. 
Hyperthyroidism is an established risk factor for 
fracture, and we have not used genetic determinants of 
hyperthyroidism risk, but rather genetic determinants 
of thyroid stimulating hormone level, which are likely 
to be different. Moreover, our study described the 
effect of clinical risk factors on fracture in the general 
population, and is therefore not generalisable to states 
or conditions of extreme circumstances known to cause 
fracture (eg, sustained vitamin D deficiency, rickets, or 
osteomalacia). Furthermore, our results apply only to 
25-hydroxy-vitamin D, and might not necessarily reflect 
effects of its active form, 1,25-dihydroxy-vitamin D. 
However, vitamin D supplementation, as is commonly 
used, acts by influencing 25-hydroxy-vitamin D. 
Altogether, the course of action for effective fracture 
prevention relies on establishing vitamin D deficiency 
and seeking its correction, rather than the widespread 
use of non-indicated ineffective supplementation.
Strengths and weaknesses of the study
To our knowledge, we have generated the largest 
and most comprehensive assessment of the genetic 
determinants of fracture risk so far. Moreover, use of 
the largest GWAS datasets available enabled adequate 
power to estimate the relation between genetically 
modified risk factors and fracture. Our study also 
had limitations. In our mendelian randomisation 
approach, we were unable to account for the sample 
overlap between the exposure and outcome GWAS 
datasets. However, we used powerful instruments to 
estimate the relation39 between the risk factors and 
the outcomes. Therefore, any sample overlap should 
not significantly bias our findings. Another potential 
limitation was that the first release of the UK Biobank 
selected some individuals based on a nested case-
control study of smoking and lung function,70 and is 
therefore subject to selection bias.71 But after excluding 
the UK Biobank from our analyses, we observed no 
significant differences. Furthermore, the majority of 
our cohorts were imputed to HapMap (instead of more 
comprehensive reference panels), which could have 
affected the number of identified loci. However, given 
our power setting, our focus was mainly on common 
variants (which are well characterised in the HapMap 
imputation panel). In addition, analysis of large 
cohorts (UK Biobank and EPIC-Norfolk) imputed to 
more recent reference panels did not yield additional 
genome wide significant loci.
Moreover, we could not assess several relevant 
clinical risk factors. For example, body mass index72-74 
could not be assessed in our mendelian randomisation 
framework because all GWAS analyses of fracture 
have been adjusted for body weight, preventing any 
inference assessment on causality. We also lacked 
power to estimate the casual relation between smoking 
and alcohol consumption: two potentially key risk 
factors for fracture. Similarly, we did not evaluate other 
risk factors that were not modifiable (such as age, sex, 
parental fracture history and body height), or those 
that have not been assessed by GWAS to yield genetic 
instruments for mendelian randomisation studies 
(such as falls, which are likely to be an important 
modifiable risk factor for fracture).75
Furthermore, factors unlikely to be predominantly 
genetic in origin (eg, occupation) might still have a role 
in the pathogenesis of fracture but could not be readily 
assessed through our mendelian randomisation 
approach. Nevertheless, proxy phenotypes for such risk 
factors are increasingly been investigated by GWAS (eg, 
education for occupation), and can be used as robust 
instruments in future research. In addition, because 
information on bone mineral density was not available 
for all study participants who were investigated for 
fracture, we could not determine directly the degree 
to which bone mineral density mediated the effect 
of genetic determinants on fracture risk. Mendelian 
randomisation is a helpful method to minimise several 
biases in observational studies, but the possibility of 
residual pleiotropy could bias estimates in this study. 
However, the likelihood of this bias is reduced because 
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the mendelian randomisation-Egger regression test 
showed no clear directional pleiotropy for most of the 
factors. Lastly, because most of the study population 
was of European ancestry, results should not be 
directly generalised to other ethnicities.
Similarly, null results of a mendelian randomisation 
study could be influenced by canalisation, which is 
defined as compensatory feedback mechanisms that 
cannot be taken into account.76 The possible influence 
of the risk factors on fracture risk might be specifically 
linked to their complications or management of the 
disease, which we also could not take into account in 
mendelian randomisation. As in most epidemiological 
studies, mendelian randomisation also assumes 
a linear relation between the risk factor and the 
outcome, which might not invariably be the case for 
all risk factors of fracture. Some risk factors, such as 
vitamin D and estimated calcium intake, could have 
non-linear threshold associations, as discussed above. 
Furthermore, we could not account for the dose-
response association (eg, between the lactose variant 
rs4988235 and dairy intake) within our design, or 
differences in biological effects across different types of 
grouped exposures (that is, fermented v non-fermented 
types of dairy products). Finally, the non-significant 
trend observed for vitamin D towards having increased 
risk of fracture could be attributed to the selection 
of healthy people (that is, participants with very low 
levels of vitamin D and fracture, as well as those who 
are older, frail, and physically impaired, could have 
been under-represented in the studies included in 
the GWAS meta-analyses). Therefore, the vitamin D 
estimates of the current study cannot be generalised to 
these groups of older people.
conclusion
From a study of over 500 000 individuals (about 
185 000 fracture cases), we provide evidence that the 
main genetic determinants of osteoporotic fracture 
also influence bone mineral density, which was the 
only clinical risk factor to have shown a major effect 
on fracture risk among the study population assessed. 
By contrast, we found that other genetically estimated 
clinical risk factors for fracture, had either a very 
modest or no effect on fracture risk in the general 
population. Notably, genetic predisposition to lower 
levels of vitamin D and estimated calcium intake 
from dairy sources were not associated with fracture 
risk. Our study confirms bone mineral density as a 
pivotal cause of osteoporotic fracture and postulates 
that, among all the clinical risk factors we evaluated, 
interventions aimed at increasing bone mineral density 
are likely to have the most clinically relevant effect on 
fracture risk reduction.
autHOr aFFiliatiONS
1Department of Internal Medicine, Erasmus MC, University Medical 
Center, Rotterdam, Netherlands
2Department of Epidemiology, Erasmus MC, University Medical 
Center, Rotterdam, Netherlands
3Lady Davis Institute, Jewish General Hospital, McGill University, 
Montréal, Québec, Canada
4Department of Human Genetics, McGill University, Montréal, 
Québec, Canada
5DaP Lab, School of Life Sciences, Westlake University and Westlake 
Institute for Advanced Study, Hangzhou, Zhejiang, China
6Institute of Aging Research and the Affiliated Hospital, School of 
Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China
7Medical Research Council Integrative Epidemiology Unit, University 
of Bristol, Bristol, UK
8University of Queensland Diamantina Institute, University of 
Queensland, Translational Research Institute, Brisbane, Australia
9Institute for Aging Research, Hebrew SeniorLife, Harvard Medical 
School, Boston, MA, USA
10Department of Medicine, Beth Israel Deaconess Medical Center 
and Harvard Medical School, Boston, MA, USA
11Centre for Bone and Arthritis Research, Department of Internal 
Medicine, Institute of Medicine, Sahlgrenska, Gothenburg, Sweden
We thank all study participants for making this work possible; the 
many colleagues who contributed to collection and phenotypic 
characterisation of the clinical samples, as well as genotyping and 
analysis of the GWAS data; and the 23andMe research team. Part of 
this work was conducted using the UK Biobank resource. Full list of 
acknowledgments, funding organisations, and grants are listed per 
cohort in the supplemental material.
The following members of the GEFOS/GENOMOS consortium and 
the 23andMe research team are coauthors of this manuscript: 
Vincenzo Forgetta, Aaron Leong, Omar S Ahmad, Charles Laurin, 
Lauren E Mokry, Stephanie Ross, Cathy E Elks, Jack Bowden, Nicole M 
Warrington, Aaron Kleinman, Sara M Willems, Daniel Wright, Felix R 
Day, Anna Murray, Katherine S Ruth, Konstantinos K Tsilidis, Cheryl L 
Ackert-Bicknell, J H Duncan Bassett, Bram C J van der Eerden, Kaare 
M Gautvik, Sjur Reppe, Graham R Williams, Carolina Medina-Gómez, 
Karol Estrada, Najaf Amin, Joshua C Bis, Stephan Breda, Daniel I 
Chasman, Serkalem Demissie, Anke W Enneman, Yi-Hsiang Hsu, 
Thorvaldur Ingvarsson, Mika Kähönen, Candace Kammerer, Andrea 
Z Lacroix, Guo Li, Ching-Ti Liu, Yongmei Liu, Mattias Lorentzon, 
Reedik Mägi, Evelin Mihailov, Lili Mlani, Alireza Moayyeri, Carrie 
M Nielson, Nerea Alonso, Pack Chung Sham, Kristin Siggeirsdotir, 
Gunnar Sigurdsson, Unnur Thorsteinsdottir, Stella Trompet, Gudmar 
Thorleifsson, Liesbeth Vandenput, Nathalie van der Velde, Jorma 
Viikari, Su-Mei Xiao, Jing Hua Zhao, Kristina E Akesson, Marianne 
Andersen, Biljana Atanasovska, Susana Balcells, Joel Eriksson, Melissa 
M Formosa, Carmen Garcia-Ibarbia, Jesús Gonzalez-Macias, Natalia 
Garcia-Giralt, Goran Hallmans, Magnus Karlsson, Rita Khusainova, 
Beom-Jun Kim, Timothy C Y Kwok, Seung Hun Lee, Ping C Leung, Hans 
Mallmin, Laura Masi, Beatrice S Melin, Simona Mencej-Bedrac, Maria 
Nethander, José M Olmos, Panagoula Kollia, Janez Prezelj, Natasja M 
van Schoor, Olle Svensson, Pawel Szulc, Carmen Valero, Jean Woo, 
Maria Brandi, Sulin Cheng, Roland Chapurlat, Claus Christiansen, Cyrus 
Cooper, George Dedoussis, John A Eisman, Morten Frost, Sylvie Giroux, 
Daniel Grinberg, David Goltzman, Lynne J Hocking, Wim Van Hul, Jung-
Min Koh, Lars Rejnmark, Jens-Erik B Jensen, Bente Langdahl, Joshua 
R Lewis, Roman S Lorenc, Elza Khusnutdinova,Janja Marc, Fiona E 
McGuigan, Dan Mellström, Karl Michaelsson, Xavier Nogues, Peter 
Nordström, Barbara Obermayer-Pietsch, Ulrika Pettersson-Kymmer, 
Richard L Prince, Jonathan Reeve, David M Reid, Jose A Riancho, 
Francois Rousseau, Nelson L S Tang, Angela Xuereb-Anastasi, William 
D Leslie, Daniel S Evans, Steven R Cummings, Jane Cauley, Cornelia 
M van Duijn, Matt Brown, Emma L Duncan, Lisette CPGM de Groot, 
Tonu Esko, Vilmundar Gudnason, Tamara B Harris, Rebecca D Jackson, 
J Wouter Jukema, M Arfan Ikram, David Karasik, Stephen Kaptoge, 
Kay-Tee Khaw, Annie Wai-Chee Kung, Terho Lehtimäki, Leo-Pekka 
Lyytikäinen, Paul Lips, Robert Luben, Andres Metspalu, Joyce B J van 
Meurs, Ryan L Minster, Eric Orwoll, Edwin Oei, Bruce M Psaty, Olli T 
Raitakari, Stuart H Ralston, Paul M Ridker, John A Robbins, Albert V 
Smith, Tim D Spector, Unnur Styrkarsdottir, Joseph Zmuda, Gregory 
J Tranah, Kari Stefansson, Andre G Uitterlinden, M Carola Zillikens, 
Evangelia E Ntzani, Evangelos Evangelou, John P A Ioannidis, John R 
B Perry, Joyce Y Tung, David A Hinds, Robert A Scott. Full details of the 
authorship, including job titles and affiliations, are included in the 
supplemental material.
23andMe research team: Michelle Agee, Babak Alipanahi, Adam 
Auton, Robert K Bell, Katarzyna Bryc, Sarah L Elson, Pierre Fontanillas, 
Nicholas A Furlotte, David A Hinds, Karen E Huber, Aaron Kleinman, 
Nadia K Litterman, Matthew H McIntyre, Joanna L Mountain, Elizabeth 
S Noblin, Carrie A M Northover, Steven J Pitts, J Fah Sathirapongsasuti, 
Olga V Sazonova, Janie F Shelton, Suyash Shringarpure, Chao Tian, 
Joyce Y Tung, Vladimir Vacic, and Catherine H Wilson. 
 o
n
 23 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3225 on 29 August 2018. Downloaded from 
RESEARCH
10 doi: 10.1136/bmj.k3155 | BMJ 2018;362:k3155 | the bmj
GEFOS/GENOMOS consortium: Vincenzo Forgetta, Aaron Leong, Omar 
S Ahmad, Charles Laurin, Lauren E Mokry, Stephanie Ross, Cathy 
E Elks, Jack Bowden, Nicole M Warrington, Sara M Willems, Daniel 
Wright, Felix R Day, Anna Murray, Katherine S Ruth, Konstantinos K 
Tsilidis, Cheryl L Ackert-Bicknell, J H Duncan Bassett, Bram C J van der 
Eerden, Kaare M Gautvik, Sjur Reppe, Graham R Williams, Carolina 
Medina-Gómez, Karol Estrada, Najaf Amin, Joshua C Bis, Stephan 
Breda, Daniel I Chasman, Serkalem Demissie, Anke W Enneman, 
Yi-Hsiang Hsu, Thorvaldur Ingvarsson, Mika Kähönen, Candace 
Kammerer, Andrea Z LaCroix, Guo Li, Ching-Ti Liu, Yongmei Liu, 
Mattias Lorentzon, Reedik Mägi, Evelin Mihailov, Lili Mlani, Alireza 
Moayyeri, Carrie M Nielson, Nerea Alonso, Pack Chung Sham, Kristin 
Siggeirsdotir, Gunnar Sigurdsson, Unnur Thorsteinsdottir, Stella 
Trompet, Gudmar Thorleifsson, Liesbeth Vandenput, Nathalie van der 
Velde, Jorma Viikari, Su-Mei Xiao, Jing Hua Zhao, Kristina E Akesson, 
Marianne Andersen, Biljana Atanasovska, Susana Balcells, Joel 
Eriksson, Melissa M Formosa, Carmen Garcia-Ibarbia, Jesús Gonzalez-
Macias, Natalia Garcia-Giralt, Goran Hallmans, Magnus Karlsson, Rita 
Khusainova, Beom-Jun Kim, Timothy C Y Kwok, Seung Hun Lee, Ping C 
Leung, Hans Mallmin, Laura Masi, Beatrice S Melin, Simona Mencej-
Bedrac, Maria Nethander, José M Olmos, Panagoula Kollia, Janez 
Prezelj, Natasja M van Schoor, Olle Svensson, Pawel Szulc, Carmen 
Valero, Jean Woo, Maria Brandi, Sulin Cheng, Roland Chapurlat, Claus 
Christiansen, Cyrus Cooper, George Dedoussis, John A Eisman, Morten 
Frost, Sylvie Giroux, Daniel Grinberg, David Goltzman, Lynne J Hocking, 
Wim Van Hul, Jung-Min Koh, Lars Rejnmark, Jens-Erik B Jensen, Bente 
Langdahl, Joshua R Lewis, Roman S Lorenc, Elza Khusnutdinova, 
Janja Marc, Fiona E McGuigan, Dan Mellström, Karl Michaelsson, 
Xavier Nogues, Peter Nordström, Barbara Obermayer-Pietsch, Ulrika 
Pettersson-Kymmer, Richard L Prince, Jonathan Reeve, David M Reid, 
Jose A Riancho, Francois Rousseau, Nelson L S Tang, Angela Xuereb-
Anastasi, William D Leslie, Daniel S Evans, Steven R Cummings, Jane 
Cauley, Cornelia M van Duijn, Matt Brown, Emma L Duncan, Lisette 
CPGM. de Groot, Tonu Esko, Vilmundar Gudnason, Tamara B Harris, 
Rebecca D Jackson, J Wouter Jukema, M Arfan Ikram, David Karasik, 
Stephen Kaptoge, Kay-Tee Khaw, Annie Wai-Chee Kung, Terho 
Lehtimäki, Leo-Pekka Lyytikäinen, Paul Lips, Robert Luben, Andres 
Metspalu, Joyce B J van Meurs, Ryan L Minster, Eric Orwoll, Edwin Oei, 
Bruce M Psaty, Olli T Raitakari, Stuart H Ralston, Paul M Ridker, John A 
Robbins, Albert V Smith, Tim D Spector, Unnur Styrkarsdottir, Joseph 
Zmuda, Gregory J Tranah, Kari Stefansson, Andre G Uitterlinden, M 
Carola Zillikens, Evangelia E Ntzani, Evangelos Evangelou, John P A 
Ioannidis, John R B Perry, and Robert A Scott.
Contributors: KT, JAM, LO, H-FZ, JBR, and FRi designed the study. KT, 
LO, H-FZ, VF, NMW, AK, NAm, JCB, SBr, SD, AWE, Y-HH, TI, CK, GL, C-TL, 
YL, RM, EM, LMi, AM, CMN, NAl, PCS, KSi, GS, ST, GT, LV, JV, S-MX, JHZ, 
MA, BA, JE, MMF, CG-I, JG-M, NG-G, GH, MKa, RK, B-JK, TCYK, SHL, PCL, 
HM, LMa, BSM, SMB, MN, JMO, JP, NvS, OS, CV, JW, SC, RC, CCh, MF, SG, 
LJH, WVH, J-MK, LR, J-EBJ, JRL, RSL, FEM, DM, XN, PN, JR, WDL, DSE, DK, 
SK, TL, L-PL, RL, JBJvM, RLM, EOe, PMR, JAR, AVS, US, JZ, GJT, MCZ, and 
DME were involved in study specific phenotyping and data analysis. 
DIC, MKä, AZL, ML, KSt, NvdV, KA, SBa, PK, PS, MBra, CCo, GD, JAE, DGr, 
DGo, BL, EK, JM, KM, BO-P, UP-K, RLP, DMR, JAR, FRo, NLST, AX-A, SRC, 
JC, CMvD, MBro, ELD, LdG, TE, VG, TBH, RDJ, JWJ, MAI, K-TK, AWCK, PL, 
AMe, EOr, BMP, OTR, SHR, TDS, UT, AGU, JYT, DAH, DPK, CO, JBR, and 
FRi were involved with study specific coordination and management. 
KT, JAM, KE, KKT, EEN, EE, and JPAI did the meta-analysis. CLA-B, JHDB, 
BCJvdE, KMG, SR, GRW, and CM-G did the functional work. KT, JAM, 
H-FZ, DME, DPK, CO, JBR, FRi, VF, AL, OSA, CL, LEM, SR, CEE, JB, SMW, 
DW, FRD, AM, KSR, JRBP, and RAS did the mendelian randomisation 
analysis. KT, JAM, JBR, and FRi wrote the first draft. KT, JAM, LO, H-FZ, 
DME, DPK, CO, JBR, and FRi wrote the final version of the paper. All 
authors reviewed the manuscript, added appropriate revisions, agreed 
to submission for publication, and approved the final version. KT, JAM, 
LO, and H-FZ (first) are equal contributing authors, and DME, DPK, 
CO, JBR, and FRi (senior) are equal contributing authors. FRi and JBR 
are the guarantors. The corresponding authors attest that all listed 
authors meet authorship criteria and that no others meeting the 
criteria have been omitted. 
Funding: This research and the Genetic Factors for Osteoporosis 
(GEFOS) consortium have been funded by the European Commission 
(HEALTH-F2-2008-201865-GEFOS). AGES: NIH contract N01-
AG-12100 and NIA Intramural Research Program, Hjartavernd (the 
Icelandic Heart Association), and Althingi (the Icelandic Parliament). 
Icelandic Heart Association. Anglo-Australasian Osteoporosis Genetics 
Consortium (AOGC): National Health and Medical Research Council 
(Australia) (grant reference 511132). Australian Cancer Research 
Foundation and Rebecca Cooper Foundation (Australia). National 
Health and Medical Research Council (Australia). National Health and 
Medical Research Council (Australia) Career Development Award 
(569807). Medical Research Council New Investigator Award (MRC 
G0800582). Health Research Council of New Zealand. Sanofi-Aventis, 
Eli Lilly, Novartis, Pfizer, Proctor & Gamble Pharmaceuticals and Roche. 
National Health and Medical Research Council, Australia. Australian 
National Health and Medical Research Council, MBF Living Well 
foundation, the Ernst Heine Family Foundation and from untied 
educational grants from Amgen, Eli Lilly International, GE-Lunar, Merck 
Australia, Novartis, Sanofi-Aventis Australia and Servier. Medical 
Research Council UK and Arthritis Research UK. The Victorian Health 
Promotion Foundation and the Geelong Region Medical Research 
Foundation, and the National Health and Medical Research Council, 
Australia (project grant 628582). Action Research UK. DME is 
supported by an Australian Research Council Future Fellowship 
(FT130101709). This work was supported by a Medical Research 
Council programme grant (MC_UU_12013/4).. B-Vitamins for the 
PRevention Of Osteoporotic Fractures (BPROOF) study: supported and 
funded so far by The Netherlands Organisation for Health Research 
and Development (ZonMw, grant 6130.0031), The Hague; 
unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; 
Orthica, Almere; Netherlands Consortium Healthy Ageing (NCHA) 
Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture and 
Innovation (project KB-15-004-003), The Hague; Wageningen 
University, Wageningen; VUmc, Amsterdam; Erasmus Medical Center, 
Rotterdam. Cardiovascular Health Study (CHS): National Heart Lung 
and Blood Institute (NHLBI) contracts HHSN268201200036C, 
HHSN268200800007C, N01HC55222, N01HC85079, 
N01HC85080, N01HC85081, N01HC85082, N01HC85083, 
N01HC85086; and NHLBI grants U01HL080295, R01HL087652, 
R01HL105756, R01HL103612, R01HL120393, and R01HL130114 
with additional contribution from the National Institute of Neurological 
Disorders and Stroke (NINDS). Additional support was provided 
through R01AG023629 from the National Institute on Ageing (NIA). 
Genotyping supported in part by the National Center for Advancing 
Translational Sciences, CTSI grant UL1TR000124, and the National 
Institute of Diabetes and Digestive and Kidney Disease Diabetes 
Research Center (DRC) grant DK063491 to the Southern California 
Diabetes Endocrinology Research Center. deCODE Genetics. 
EPIC-Norfolk: Medical Research Council G9321536 and G9800062, 
MAFF AN0523, EU FP5 (QLK6-CT-2002-02629), Food Standards 
Agency N05046, GEFOS EU FP7 Integrated Project Grant Reference: 
201865, The UK’s National Institute for Health Research (NIHR) 
Biomedical Research Centre Grant to Cambridge contributed to the 
costs of genotyping. Estonian Genome Center University of Tartu 
(EGCUT): This study was supported by EU H2020 grants 692145, 
676550, 654248, Estonian Research Council Grant IUT20-60, NIASC 
and EIT—Health and EU through the European Regional Development 
Fund (project No 2014-2020.4.01.15-0012 GENTRANSMED). 
Erasmus Rucphen Family Study (ERF): Netherlands Organisation for 
Scientific Research (NWO), Erasmus University Medical Centre, the 
Centre for Medical Systems Biology (CMSB1 and CMSB2) of the 
Netherlands Genomics Initiative (NGI). Framingham Osteoporosis 
Study (FOS): National Institute for Arthritis, Musculoskeletal and Skin 
Diseases and National Institute on Ageing (R01 AR41398; DPK and 
R01 AR 050066; DK National Heart, Lung, and Blood Institute’s 
Framingham Heart Study (N01-HC-25195) and its contract with 
Affymetrix for genotyping services (N02-HL-6-4278). The Gothenburg 
Osteoporosis and Obesity Determinan Study (GOOD): Swedish 
Research Council (K2010-54X-09894-19-3, 2006-3832 and 
K2010-52X-20229-05-3), Swedish Foundation for Strategic 
Research, ALF/LUA research grant in Gothenburg, Lundberg 
Foundation, Torsten and Ragnar Söderberg’s Foundation, Västra 
Götaland Foundation, Göteborg Medical Society, Novo Nordisk 
Foundation, and European Commission grant HEALTH-F2-2008-
201865-GEFOS. Health Aging and Body Composition Study 
(HealthABC): the Intramural Research Program of the National Institute 
of Health (NIH), National Institute on Ageing. US National Institute of 
Ageing (NIA) contracts N01AG62101, N01AG62103, and 
N01AG62106. NIA grant 1R01AG032098. The Center for Inherited 
Disease Research (CIDR). National Institutes of Health contract 
number HHSN268200782096C. Hong Kong Osteoporosis Study 
(HKOS): Hong Kong Research Grant Council (HKU 768610M); Bone 
Health Fund of HKU Foundation; KC Wong Education Foundation; 
Small Project Funding (201007176237); Matching Grant, Committee 
on research and conference (CRCG) Grant and Osteoporosis and 
Endocrine Research Fund; and the Genomics Strategic Research 
Theme of the University of Hong Kong. The Osteoporotic Fractures in 
Men (MrOS) Study is supported by National Institutes of Health 
funding. The following institutes provide support: National Institute of 
Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National 
 o
n
 23 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3225 on 29 August 2018. Downloaded from 
RESEARCH
the bmj | BMJ 2018;362:k3225 | doi: 10.1136/bmj.k3225 11
Institute on Ageing (NIA), National Center for Research Resources 
(NCRR), and National Institute of Health (NIH) Roadmap for Medical 
Research under the following grant numbers: U01 AR45580, U01 
AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 
AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. 
Prospective study of pravastatin in the elderly at risk (PROSPER): 
European Union’s Seventh Framework Programme (FP7/2007-2013) 
under grant agreement No HEALTH-F2-2009-223004 PHASE. 
Rotterdam study I, Rotterdam study II, Rotterdam study III: 
Netherlands Organisation of Scientific Research (NWO) Investments 
(No 175.010.2005.011, 911-03-012); Research Institute for 
Diseases in the Elderly (014-93-015; RIDE2); Netherlands Genomics 
Initiative/Netherlands Consortium for Healthy Ageing (050-060-810); 
German Bundesministerium fuer Forschung und Technology under 
grants #01 AK 803 A-H and # 01 IG 07015 G. the Netherlands 
Organisation for Health Research and Development ZonMw VIDI 
016.136.367 (funding FR, CM-G, KT). Study of Osteoporotic Fractures 
(SOF): supported by National Institutes of Health funding. The National 
Institute on Ageing (NIA) and the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases (NIAMS) provides support under 
the following grant numbers: R01 AG005407, R01 AR35582, R01 
AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 
AG027576, and R01 AG026720. TwinsUK1, TwinsUK2: NIHR 
Biomedical Research Centre (grant to Guys’ and St Thomas’ Hospitals 
and King’s College London); Chronic Disease Research Foundation; 
Wellcome Trust; Canadian Institutes of Health Research, Canadian 
Foundation for Innovation, Fonds de la Recherche en Santé Québec, 
Lady Davis Institute, Jewish General Hospital, and Ministère du 
Développement économique, de l’Innovation et de l’Exportation du 
Quebec. UK Biobank: This research has been conducted using the UK 
Biobank Resource (application No 12703). Access to the UK Biobank 
study data was funded by a University of Queensland Early Career 
Researcher Grant (2014002959). Access to the UK Biobank study 
data was funded by University of Queensland Early Career Researcher 
Grant (2014002959) and University of Western Australia-University 
of Queensland Bilateral Research Collaboration Award 
(2014001711). NMW is supported by a National Health and Medical 
Research Council Early Career Fellowship (APP1104818). Women’s 
Genome Health Study (WGHS): HL 043851 and HL69757 from the 
National Heart, Lung, and Blood Institute and CA 047988 from the 
National Cancer Institute, the Donald W Reynolds Foundation, and the 
Fondation Leducq Amgen. Women’s Health Initiative (WHI) program is 
funded by the National Heart, Lung, and Blood Institute, National 
Institutes of Health, US. Department of Health and Human Services 
through contracts N01WH22110, 24152, 32100-2, 32105-6, 
32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 
42129-32, and 44221. Young Finns study (YFS): has been financially 
supported by the Academy of Finland: grants 286284 (TL), 134309 
(Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), 
and 41071 (Skidi); the Social Insurance Institution of Finland; 
Competitive State Research Financing of the Expert Responsibility 
area of Tampere, Turku and Kuopio University Hospitals (grant 
X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish 
Foundation for Cardiovascular Research; Finnish Cultural Foundation; 
Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö 
Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and 
Diabetes Research Foundation of Finnish Diabetes Association; and 
EU Horizon 2020 (grant 755320 for TAXINOMISIS). Barcelona cohort 
osteoporosis (BARCOS): Red de Envejecimiento y fragilidad RETICEF, 
CIBERER, Instituto Carlos III. Fondos FEDER. Fondo de Investigación 
Sanitaria (FIS PI13/00116). Spanish MINECO (SAF2014-56562-R), 
Catalan Government (2014SGR932). Austrios-A, Austrios-B: was 
supported by BioPersMed (COMET K project 825329), and the 
Competence Center CBmed (COMET K1 centre 844609), funded by 
the Austrian Federal Ministry of Transport, Innovation and Technology 
(BMVIT) and the Austrian Federal Ministry of Economics and Labour/
the Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ) 
and the Styrian Business Promotion Agency (SFG). Cantabria-Camargo 
study (Cabrio-C), Cantabria osteoporosis case-control study 
(Cabrio-CC): Instituto de Salud Carlos III-Fondo de Investigaciones 
Sanitarias Grants PI 06/34,PI09/539, PI12/615 and PI15/521 (that 
could be cofunded by European Union-FEDER funds). Calcium Intake 
Fracture Outcome Study (CAIFOS): Healthway Health Promotion 
Foundation of Western Australia, Australasian Menopause Society and 
the Australian National Health and Medical Research Council Project 
Grant (254627, 303169 and 572604). Canadian Multicentre 
Osteoporosis Study (CaMos): was supported by a grant from the 
Canadian Institutes for Health Research (CIHR) (grant No 
MOP111103). JBR and JAM are funded by the Canadian Institutes of 
Health Research, Fonds du Recherche Québec Santé, and Jewish 
General Hospital. Edinburgh Osteoporosis Study (EDOS): was 
supported by a grant from Arthritis Research UK (grant number 
15389). European Prospective Osteoporosis Study (EPOS): EU 
Biomed 1 (BMHICT920182, CIPDCT925012, ERBC1PDCT 940229, 
ERBC1PDCT930105), Medical Research Council G9321536 and 
G9800062, Wellcome Trust Collaborative Research Initiative 1995, 
MAFF AN0523,EU FP5 (QLK6-CT-2002-02629), Food Standards 
Agency N05046, GEFOS EU FP7 Integrated Project Grant Reference: 
201865. The UK’s National Institute for Health Research (NIHR) 
Biomedical Research Centre Grant to Cambridge contributed to the 
costs of genotyping. Geelong Osteoporosis Study (GEOS): Canadian 
Institutes for health research operating grant funding reference 
#86748. Genetic analysis of osteoporosis in Greece (GROS): 
University of Athens, Greece (Kapodistrias 2009). Hertfordshire Cohort 
Study (HCS): supported by Medical Research Council UK; Arthritis 
Research UK; National Institute for Health Research (NIHR) 
Musculoskeletal BRU Oxford; National Institute for Health Research 
(NIHR) Nutrition BRC Southampton. Hong Kong: The projects have 
been supported by The Hong Kong Jockey Club Charities Trust, VC 
discretionary fund of The Chinese University of Hong Kong, and 
Research Grants Council Earmarked Grant CUHK4101/02M. Korean 
osteoporosis study in Asan Medical Center (KorAMC): a grant of the 
Korea Health Technology R&D Project, the Ministry of Health and 
Welfare, Republic of Korea (project No HI14C2258); a grant of the 
Korea Health Technology R&D Project, the Ministry of Health and 
Welfare, Republic of Korea (project No HI15C0377). Longitudinal 
Aging Study Amsterdam (LASA): largely supported by a grant from the 
Netherlands Ministry of Health Welfare and Sports, Directorate of Long 
term Care. MINOS study was supported by a grant from the 
Merck-Sharp-Dohme Chibret company. Malta osteoporotic fracture 
study (MOFS): financial support was received from the European 
Union Strategic Educational Pathways Scholarhip scheme (STEPS). The 
Osteoporotic Fractures in Men (MrOS) Sweden: financial support was 
received from the Swedish Research Council (K2010-
54X-09894-19-3, 2006-3832), Swedish Foundation for Strategic 
Research, ALF/LUA research grant in Gothenburg, Lundberg 
Foundation, Torsten and Ragnar Söderberg’s Foundation, Västra 
Götaland Foundation, Göteborg Medical Society, Novo Nordisk 
foundation, and European Commission grant HEALTH-F2-2008-
201865-GEFOS. Odense androgen study (OAS): World Anti-Doping 
Agency, Danish Ministry of Culture, Institute of Clinical Research of the 
University of Southern Denmark. Prevalence of osteoporosis in 
Slovenia (Slo-preval): was created as part of projects financially 
supported by the Slovenian research agency: P3-298 Geni, Hormoni 
in osebnostne spremembe pri hormonskih motnjah; Z1-3238: Genski 
in okoljski dejavniki tveganja za razvoj motnje pri remodellaciji kosti; 
J2-3314 Genetski faktorji in hormoni pri presnovnih boleznih; and 
J3-2330 Genetski dejavniki pri osteoporozi. TWINGENE: supported in 
part by the Ragnar Söderberg Foundation (E9/11); the National 
Science Foundation (EArly Concept Grants for Exploratory Research: 
“Workshop for the Formation of a Social Science Genetic Association 
Consortium,” SES-1064089) as supplemented by the National 
Institutes of Health’s (NIH) Office of Behavioural and Social Sciences 
Research; and the National Institute on Ageing/NIH through Grants 
P01-AG005842, P01-AG005842-20S2, P30-AG012810, and 
T32-AG000186-23 to the National Bureau of Economic Research. The 
Swedish Twin Registry is supported by the Swedish Department of 
Higher Education, European Commission European Network for 
Genetic and Genomic Epidemiology (ENGAGE: 7th Framework 
Program (FP7/2007-2013)/Grant agreement 
HEALTH-F4-2007-201413; and GenomEUtwin: 5th Framework 
program “Quality of Life and Management of the Living Resources” 
Grant QLG2-CT-2002-01254); NIH (DK U01-066134); Swedish 
Research Council (M-2005-1112 and 2009-2298); Swedish 
Foundation for Strategic Research (ICA08-0047); Jan Wallander and 
Tom Hedelius Foundation; and Swedish Council for Working Life and 
Social Research. The Umeå Fracture and Osteoporosis Study (UFO) is 
supported by the Swedish Research Council (K20006-
72X-20155013), Swedish Sports Research Council (87/06), Swedish 
Society of Medicine, Kempe-Foundation (JCK-1021), and by grants 
from the Medical Faculty of Umeå University (ALFVLL:968:22-2005, 
ALFVL:-937-2006, ALFVLL:223:11-2007, ALFVLL:78151-2009) and 
county council of Västerbotten (SpjutspetsanslagVLL:159:33-2007). 
GRW and JHDB were funded by the Wellcome Trust (Strategic Award 
grant No 101123; Joint Investigator Award No 110141; project grant 
No 094134). DPK was funded by a grant from the National Institute 
on Arthritis Musculoskeletal and Skin Diseases R01 AR041398. The 
funding agencies had no role in the study design, analysis, or 
interpretation of data; the writing of the manuscript; or in the decision 
to submit the article for publication. 
 o
n
 23 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3225 on 29 August 2018. Downloaded from 
RESEARCH
12 doi: 10.1136/bmj.k3155 | BMJ 2018;362:k3155 | the bmj
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: 
support from the organisations listed in the funding statement for the 
submitted work; BMP serves on the data safety monitoring board of 
a clinical trial funded by the manufacturer (Zoll LifeCor) and on the 
Steering Committee of the Yale Open Data Access Project funded by 
Johnson and Johnson; CEE is currently employed by AstraZeneca; 
SR has received grants from Eli Lilly, Amgen, UCB, and Ultragenyx, 
and has provided consultation for Novartis; KE is currently employed 
by Biogen; US, UT, GT, and KSt are employed by deCODE genetics/
Amgen; and AK, JYT, and DAH are employed by 23andMe, and hold 
stock or stock options in 23andMe.
Ethical approval: The different cohorts had approvals from respective 
national ethical committees for medical research.
Data sharing: All data are available for unrestricted use through the 
GEFOS consortium and can be downloaded here: http://www.gefos.
org/. We request that all use of such data be properly attributed 
through citation of this article.
Transparency: The corresponding authors (JBR and FRi) affirm that 
the manuscript is an honest, accurate, and transparent account of the 
study being reported; that no important aspects of the study have 
been omitted; and that any discrepancies from the study as planned 
(and, if relevant, registered) have been explained.
This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which 
permits others to distribute, remix, adapt and build upon this work, 
for commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1  Melorose  J, Perroy  R, Careas  S. World population 
prospects. United Nations, 2015. doi:10.1017/
CBO9781107415324.004.
2  Harvey  N, Dennison  E, Cooper  C. Osteoporosis: impact on health 
and economics [correction in: Nat Rev Rheumatol 2010;6:184]. Nat 
Rev Rheumatol 2010;6:99-105. doi:10.1038/nrrheum.2009.260 
3  Cooper  C, Melton  LJ. Magnitude and impact of osteoporosis and 
fractures. Academic Press, 1996.
4  Kanis  JA, Hans  D, Cooper  C, et al, Task Force of the FRAX Initiative. 
Interpretation and use of FRAX in clinical practice. Osteoporos 
Int 2011;22:2395-411. doi:10.1007/s00198-011-1713-z 
5  Nguyen  ND, Frost  SA, Center  JR, Eisman  JA, Nguyen  TV. 
Development of a nomogram for individualizing hip fracture risk in 
men and women. Osteoporos Int 2007;18:1109-17. doi:10.1007/
s00198-007-0362-8 
6  Nguyen  ND, Eisman  JA, Center  JR, Nguyen  TV. Risk factors for 
fracture in nonosteoporotic men and women. J Clin Endocrinol 
Metab 2007;92:955-62. doi:10.1210/jc.2006-1476 
7  Khosla  S, Shane  E. A crisis in the treatment of osteoporosis. J Bone 
Miner Res 2016;31:1485-7. doi:10.1002/jbmr.2888 
8  Andrew  T, Antioniades  L, Scurrah  KJ, Macgregor  AJ, Spector  TD. 
Risk of wrist fracture in women is heritable and is influenced by genes 
that are largely independent of those influencing BMD. J Bone Miner 
Res 2005;20:67-74. doi:10.1359/JBMR.041015 
9  Michaëlsson  K, Melhus  H, Ferm  H, Ahlbom  A, Pedersen  NL. Genetic 
liability to fractures in the elderly. Arch Intern Med 2005;165:1825-
30. doi:10.1001/archinte.165.16.1825 
10  Smith  GD, Ebrahim  S. ‘Mendelian randomization’: can genetic 
epidemiology contribute to understanding environmental 
determinants of disease? Int J Epidemiol 2003;32:1-22. 
doi:10.1093/ije/dyg070 
11  Estrada  K, Styrkarsdottir  U, Evangelou  E, et al. Genome-wide 
meta-analysis identifies 56 bone mineral density loci and reveals 14 
loci associated with risk of fracture. Nat Genet 2012;44:491-501. 
doi:10.1038/ng.2249 
12  Day  FR, Ruth  KS, Thompson  DJ, et al, PRACTICAL consortium, 
kConFab Investigators, AOCS Investigators, Generation Scotland, 
EPIC-InterAct Consortium, LifeLines Cohort Study. Large-scale 
genomic analyses link reproductive aging to hypothalamic signaling, 
breast cancer susceptibility and BRCA1-mediated DNA repair. Nat 
Genet 2015;47:1294-303. doi:10.1038/ng.3412 
13  Okada  Y, Wu  D, Trynka  G, et al, RACI consortium, GARNET 
consortium. Genetics of rheumatoid arthritis contributes to biology 
and drug discovery. Nature 2014;506:376-81. doi:10.1038/
nature12873 
14  Jostins  L, Ripke  S, Weersma  RK, et al, International IBD 
Genetics Consortium (IIBDGC). Host-microbe interactions have 
shaped the genetic architecture of inflammatory bowel disease. 
Nature 2012;491:119-24. doi:10.1038/nature11582 
15  Bradfield  JP, Qu  H-Q, Wang  K, et al. A genome-wide meta-analysis 
of six type 1 diabetes cohorts identifies multiple associated 
loci. PLoS Genet 2011;7:e1002293. doi:10.1371/journal.
pgen.1002293 
16  Porcu  E, Medici  M, Pistis  G, et al. A meta-analysis of thyroid-
related traits reveals novel loci and gender-specific differences in 
the regulation of thyroid function. PLoS Genet 2013;9:e1003266. 
doi:10.1371/journal.pgen.1003266 
17  van Meurs  JBJ, Dhonukshe-Rutten  RAM, Pluijm  SMF, et al. 
Homocysteine levels and the risk of osteoporotic fracture. N Engl J 
Med 2004;350:2033-41. doi:10.1056/NEJMoa032546 
18  Willems  SM, Wright  DJ, Day  FR, et al, GEFOS Any-Type of Fracture 
Consortium. Large-scale GWAS identifies multiple loci for hand grip 
strength providing biological insights into muscular fitness. Nat 
Commun 2017;8:16015. doi:10.1038/ncomms16015 
19  Perry  JRB, Day  F, Elks  CE, et al, Australian Ovarian Cancer Study, 
GENICA Network, kConFab, LifeLines Cohort Study, InterAct 
Consortium, Early Growth Genetics (EGG) Consortium. Parent-of-
origin-specific allelic associations among 106 genomic loci for age at 
menarche. Nature 2014;514:92-7. doi:10.1038/nature13545 
20  Scott  RA, Lagou  V, Welch  RP, et al, DIAbetes Genetics Replication 
and Meta-analysis (DIAGRAM) Consortium. Large-scale association 
analyses identify new loci influencing glycemic traits and 
provide insight into the underlying biological pathways. Nat 
Genet 2012;44:991-1005. doi:10.1038/ng.2385 
21  Wessel  J, Chu  AY, Willems  SM, et al, EPIC-InterAct Consortium. 
Low-frequency and rare exome chip variants associate 
with fasting glucose and type 2 diabetes susceptibility. Nat 
Commun 2015;6:5897. doi:10.1038/ncomms6897 
22  Deloukas  P, Kanoni  S, Willenborg  C, et al, CARDIoGRAMplusC4D 
Consortium, DIAGRAM Consortium, CARDIOGENICS Consortium, 
MuTHER Consortium, Wellcome Trust Case Control Consortium. Large-
scale association analysis identifies new risk loci for coronary artery 
disease. Nat Genet 2013;45:25-33. doi:10.1038/ng.2480 
23  Morris  AP, Voight  BF, Teslovich  TM, et al, Wellcome Trust Case 
Control Consortium, Meta-Analyses of Glucose and Insulin-related 
traits Consortium (MAGIC) Investigators, Genetic Investigation 
of ANthropometric Traits (GIANT) Consortium, Asian Genetic 
Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium, 
South Asian Type 2 Diabetes (SAT2D) Consortium, DIAbetes Genetics 
Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale 
association analysis provides insights into the genetic architecture 
and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981-
90. doi:10.1038/ng.2383 
24  Mokry  LE, Ross  S, Ahmad  OS, et al. Vitamin D and risk of multiple 
sclerosis: a Mendelian randomization study [correction in: PLoS Med 
2016;13:e1001981]. PLoS Med 2015;12:e1001866. doi:10.1371/
journal.pmed.1001866 
25  Wang  TJ, Zhang  F, Richards  JB, et al. Common genetic determinants 
of vitamin D insufficiency: a genome-wide association study. 
Lancet 2010;376:180-8. doi:10.1016/S0140-6736(10)60588-0 
26  Ding  M, Huang  T, Bergholdt  HK, Nordestgaard  BG, Ellervik  C, Qi  L, 
CHARGE Consortium. Dairy consumption, systolic blood pressure, 
and risk of hypertension: Mendelian randomization study [correction 
in: BMJ 2017;358:j3550]. BMJ 2017;356:j1000. doi:10.1136/bmj.
j1000 
27  Zheng  HF, Forgetta  V, Hsu  Y-H, et al, AOGC Consortium, UK10K 
Consortium. Whole-genome sequencing identifies EN1 as a 
determinant of bone density and fracture. Nature 2015;526:112-7. 
doi:10.1038/nature14878 
28  Mackey  DC, Lui  L-Y, Cawthon  PM, et al, Study of Osteoporotic 
Fractures (SOF) and Osteoporotic Fractures in Men Study (MrOS) 
Research Groups. High-trauma fractures and low bone mineral 
density in older women and men. JAMA 2007;298:2381-8. 
doi:10.1001/jama.298.20.2381 
29  Sanders  KM, Pasco  JA, Ugoni  AM, et al. The exclusion of high trauma 
fractures may underestimate the prevalence of bone fragility fractures 
in the community: the Geelong Osteoporosis Study. J Bone Miner 
Res 1998;13:1337-42. doi:10.1359/jbmr.1998.13.8.1337 
30  Enattah  NS, Sahi  T, Savilahti  E, Terwilliger  JD, Peltonen  L, Järvelä  I. 
Identification of a variant associated with adult-type hypolactasia. 
Nat Genet 2002;30:233-7. doi:10.1038/ng826 
31  Koek  WNH, van Meurs  JB, van der Eerden  BC, et al. The T-13910C 
polymorphism in the lactase phlorizin hydrolase gene is associated 
with differences in serum calcium levels and calcium intake. J Bone 
Miner Res 2010;25:1980-7. doi:10.1002/jbmr.83 
32  Frank  J, Cichon  S, Treutlein  J, et al. Genome-wide significant 
association between alcohol dependence and a variant in the ADH 
gene cluster. Addict Biol 2012;17:171-80. doi:10.1111/j.1369-
1600.2011.00395.x 
33  Gelernter  J, Kranzler  HR, Sherva  R, et al. Genome-wide 
association study of alcohol dependence:significant findings in 
African- and European-Americans including novel risk loci. Mol 
Psychiatry 2014;19:41-9. doi:10.1038/mp.2013.145 
34  Taylor  AE, Fluharty  ME, Bjørngaard  JH, et al. Investigating the 
possible causal association of smoking with depression and 
anxiety using Mendelian randomisation meta-analysis: the 
CARTA consortium. BMJ Open 2014;4:e006141. doi:10.1136/
bmjopen-2014-006141 
 o
n
 23 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3225 on 29 August 2018. Downloaded from 
RESEARCH
the bmj | BMJ 2018;362:k3225 | doi: 10.1136/bmj.k3225 13
35  O’Seaghdha  CM, Wu  H, Yang  Q, et al, SUNLIGHT Consortium, 
GEFOS Consortium. Meta-analysis of genome-wide 
association studies identifies six new Loci for serum calcium 
concentrations. PLoS Genet 2013;9:e1003796. doi:10.1371/
journal.pgen.1003796 
36  Locke  AE, Kahali  B, Berndt  SI, et al, LifeLines Cohort 
Study, ADIPOGen Consortium, AGEN-BMI Working Group, 
CARDIOGRAMplusC4D Consortium, CKDGen Consortium, GLGC, ICBP, 
MAGIC Investigators, MuTHER Consortium, MIGen Consortium, PAGE 
Consortium, ReproGen Consortium, GENIE Consortium, International 
Endogene Consortium. Genetic studies of body mass index yield 
new insights for obesity biology. Nature 2015;518:197-206. 
doi:10.1038/nature14177 
37  Bulik-Sullivan  BK, Loh  P-R, Finucane  HK, et al, Schizophrenia 
Working Group of the Psychiatric Genomics Consortium. LD Score 
regression distinguishes confounding from polygenicity in genome-
wide association studies. Nat Genet 2015;47:291-5. doi:10.1038/
ng.3211 
38  Burgess  S, Butterworth  A, Thompson  SG. Mendelian randomization 
analysis with multiple genetic variants using summarized data. Genet 
Epidemiol 2013;37:658-65. doi:10.1002/gepi.21758 
39  Pierce  BL, Burgess  S. Efficient design for Mendelian 
randomization studies: subsample and 2-sample instrumental 
variable estimators. Am J Epidemiol 2013;178:1177-84. 
doi:10.1093/aje/kwt084 
40  Mokry  LE, Ross  S, Ahmad  OS, et al. Vitamin D and risk of multiple 
sclerosis: a Mendelian randomization study [correction in: PLoS Med 
2016;13:e1001981]. PLoS Med 2015;12:e1001866. doi:10.1371/
journal.pmed.1001866 
41  Dastani  Z, Hivert  M-F, Timpson  N, et al, DIAGRAM+ Consortium, 
MAGIC Consortium, GLGC Investigators, MuTHER Consortium, 
DIAGRAM Consortium, GIANT Consortium, Global B Pgen Consortium, 
Procardis Consortium, MAGIC investigators, GLGC Consortium. Novel 
loci for adiponectin levels and their influence on type 2 diabetes 
and metabolic traits: a multi-ethnic meta-analysis of 45,891 
individuals. PLoS Genet 2012;8:e1002607. doi:10.1371/journal.
pgen.1002607 
42  Johnson T. Efficient calculation for multi-SNP genetic risk scores. 
2012; 2012.
43  Bowden  J, Davey Smith  G, Burgess  S. Mendelian randomization with 
invalid instruments: effect estimation and bias detection through 
Egger regression. Int J Epidemiol 2015;44:512-25. doi:10.1093/ije/
dyv080 
44  Gage  SH, Jones  HJ, Burgess  S, et al. Assessing causality in 
associations between cannabis use and schizophrenia risk: a two-
sample Mendelian randomization study. Psychol Med 2017;47:971-
80. doi:10.1017/S0033291716003172 
45  Brion  M-JA, Shakhbazov  K, Visscher  PM. Calculating 
statistical power in Mendelian randomization studies. Int J 
Epidemiol 2013;42:1497-501. doi:10.1093/ije/dyt179 
46  Richards  JB, Rivadeneira  F, Inouye  M, et al. Bone mineral 
density, osteoporosis, and osteoporotic fractures: a genome-wide 
association study. Lancet 2008;371:1505-12. doi:10.1016/S0140-
6736(08)60599-1 
47  Rivadeneira  F, Styrkársdottir  U, Estrada  K, et al, Genetic Factors 
for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-
density loci identified by large-scale meta-analysis of genome-wide 
association studies. Nat Genet 2009;41:1199-206. doi:10.1038/
ng.446 
48  Styrkarsdottir  U, Halldorsson  BV, Gretarsdottir  S, et al. New 
sequence variants associated with bone mineral density. Nat 
Genet 2009;41:15-7. doi:10.1038/ng.284 
49  Styrkarsdottir  U, Halldorsson  BV, Gretarsdottir  S, et al. Multiple 
genetic loci for bone mineral density and fractures. N Engl J 
Med 2008;358:2355-65. doi:10.1056/NEJMoa0801197 
50  Duncan  EL, Danoy  P, Kemp  JP, et al. Genome-wide association 
study using extreme truncate selection identifies novel 
genes affecting bone mineral density and fracture risk. PLoS 
Genet 2011;7:e1001372. doi:10.1371/journal.pgen.1001372 
51  Zheng  H-F, Tobias  JH, Duncan  E, et al. WNT16 influences bone 
mineral density, cortical bone thickness, bone strength, and 
osteoporotic fracture risk. PLoS Genet 2012;8:e1002745. 
doi:10.1371/journal.pgen.1002745 
52  Medina-Gomez  C, Kemp  JP, Estrada  K, et al. Meta-analysis of 
genome-wide scans for total body BMD in children and adults 
reveals allelic heterogeneity and age-specific effects at the WNT16 
locus. PLoS Genet 2012;8:e1002718. doi:10.1371/journal.
pgen.1002718 
53  Visscher  PM, Brown  MA, McCarthy  MI, Yang  J. Five years of 
GWAS discovery. Am J Hum Genet 2012;90:7-24. doi:10.1016/j.
ajhg.2011.11.029 
54  Ahmad  OS, Leong  A, Miller  JA, et al. A Mendelian randomization 
study of the effect of type-2 diabetes and glycemic traits on bone 
mineral density. J Bone Miner Res 2017;32:1072-81. doi:10.1002/
jbmr.3063. 
55  Richards  JB, Zheng  H-F, Spector  TD. Genetics of osteoporosis 
from genome-wide association studies: advances and 
challenges [correction in: Nat Rev Genet 2012;13:672]. Nat Rev 
Genet 2012;13:576-88. doi:10.1038/nrg3228 
56  Hurle  MR, Nelson  MR, Agarwal  P, Cardon  LR. Trial watch: 
Impact of genetically supported target selection on R&D 
productivity. Nat Rev Drug Discov 2016;15:596-7. doi:10.1038/
nrd.2016.164 
57  Papaioannou  A, Morin  S, Cheung  AM, et al, Scientific Advisory 
Council of Osteoporosis Canada. 2010 clinical practice guidelines for 
the diagnosis and management of osteoporosis in Canada: summary. 
CMAJ 2010;182:1864-73. doi:10.1503/cmaj.100771 
58  Kanis  JA, McCloskey  EV, Johansson  H, Cooper  C, Rizzoli  R, 
Reginster  JY, Scientific Advisory Board of the European Society 
for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis 
(ESCEO) and the Committee of Scientific Advisors of the 
International Osteoporosis Foundation (IOF). European guidance for 
the diagnosis and management of osteoporosis in postmenopausal 
women. Osteoporos Int 2013;24:23-57. doi:10.1007/s00198-012-
2074-y 
59  Rooney  MR, Harnack  L, Michos  ED, Ogilvie  RP, Sempos 
CT, Lutsey  PL. Trends in use of high-dose vitamin D 
supplements exceeding 1000 or 4000 international units 
daily, 1999-2014. JAMA 2017;317:2448-50. doi:10.1001/
jama.2017.4392 
60  Leong  A, Rehman  W, Dastani  Z, et al, METASTROKE. The 
causal effect of vitamin D binding protein (DBP) levels on calcemic 
and cardiometabolic diseases: a Mendelian randomization 
study. PLoS Med 2014;11:e1001751. doi:10.1371/journal.
pmed.1001751 
61  Li  S-S, Gao  L-H, Zhang  X-Y, et al. Genetically low vitamin D levels, 
bone mineral density, and bone metabolism markers: a Mendelian 
randomisation study. Sci Rep 2016;6:33202. doi:10.1038/
srep33202 
62  Larsson  SC, Melhus  H, Michaëlsson  K. Circulating serum 
25-hydroxyvitamin D levels and bone mineral density: Mendelian 
randomization study. J Bone Miner Res 2018;33:840-4. 
doi:10.1002/jbmr.3389. 
63  Larsson  SC, Burgess  S, Michaëlsson  K. Association of genetic 
variants related to serum calcium levels with coronary artery disease 
and myocardial infarction. JAMA 2017;318:371-80. doi:10.1001/
jama.2017.8981 
64  Bauer  DC. Clinical practice. Calcium supplements and fracture 
prevention. N Engl J Med 2013;369:1537-43. doi:10.1056/
NEJMcp1210380 
65  Bergman  GJD, Fan  T, McFetridge  JT, Sen  SS. Efficacy of vitamin 
D
3 supplementation in preventing fractures in elderly women: 
a meta-analysis. Curr Med Res Opin 2010;26:1193-201. 
doi:10.1185/03007991003659814 
66  Bischoff-Ferrari  HA, Willett  WC, Orav  EJ, et al. A pooled analysis 
of vitamin D dose requirements for fracture prevention [correction 
in: N Engl J Med 2012;367:481]. N Engl J Med 2012;367:40-9. 
doi:10.1056/NEJMoa1109617 
67  Tang  BM, Eslick  GD, Nowson  C, Smith  C, Bensoussan  A. Use of 
calcium or calcium in combination with vitamin D supplementation to 
prevent fractures and bone loss in people aged 50 years and older: 
a meta-analysis. Lancet 2007;370:657-66. doi:10.1016/S0140-
6736(07)61342-7 
68  Zhao  J-G, Zeng  X-T, Wang  J, Liu  L. Association between 
calcium or vitamin D supplementation and fracture 
incidence in community-dwelling older adults: a systematic review 
and meta-analysis. JAMA 2017;318:2466-82. doi:10.1001/
jama.2017.19344 
69  Schuit  SCE, van der Klift  M, Weel  AEAM, et al. Fracture incidence and 
association with bone mineral density in elderly men and women: 
the Rotterdam Study. Bone 2004;34:195-202. doi:10.1016/j.
bone.2003.10.001 
70  Wain  LV, Shrine  N, Miller  S, et al, UK Brain Expression Consortium 
(UKBEC), OxGSK Consortium. Novel insights into the genetics 
of smoking behaviour, lung function, and chronic obstructive 
pulmonary disease (UK BiLEVE): a genetic association study in UK 
Biobank. Lancet Respir Med 2015;3:769-81. doi:10.1016/S2213-
2600(15)00283-0 
71  Munafò  MR, Tilling  K, Taylor  AE, Evans  DM, Davey Smith  G. Collider 
scope: when selection bias can substantially influence observed 
associations. Int J Epidemiol 2018;47:226-35. doi:10.1093/ije/
dyx206 
72  De Laet  C, Kanis  JA, Odén  A, et al. Body mass index as a predictor 
of fracture risk: a meta-analysis. Osteoporos Int 2005;16:1330-8. 
doi:10.1007/s00198-005-1863-y 
73  Johansson  H, Kanis  JA, Odén  A, et al. A meta-analysis of the 
association of fracture risk and body mass index in women. J Bone 
Miner Res 2014;29:223-33. doi:10.1002/jbmr.2017 
74  Compston  JE, Flahive  J, Hosmer  DW, et al, GLOW Investigators. 
Relationship of weight, height, and body mass index with fracture 
 o
n
 23 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3225 on 29 August 2018. Downloaded from 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
risk at different sites in postmenopausal women: the Global 
Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner 
Res 2014;29:487-93. doi:10.1002/jbmr.2051 
75  El-Khoury  F, Cassou  B, Charles  M-A, Dargent-Molina  P. The 
effect of fall prevention exercise programmes on fall induced 
injuries in community dwelling older adults: systematic 
review and meta-analysis of randomised controlled trials. 
BMJ 2013;347:f6234.
76  Lawlor  DA, Harbord  RM, Sterne  JAC, Timpson  N, Davey Smith  G. 
Mendelian randomization: using genes as instruments for making 
causal inferences in epidemiology. Stat Med 2008;27:1133-63. 
doi:10.1002/sim.3034
Web appendix: Supplementary note and full list of 
authorship details
 o
n
 23 July 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3225 on 29 August 2018. Downloaded from 
